Skip to main content
. 2020 Jul 15;10:11668. doi: 10.1038/s41598-020-68603-0

Table 2.

Hazard ratios and 95% confidence intervals for the incidence of end-stage renal disease by quartiles of baseline gamma-glutamyl transferase and average successive variability of gamma-glutamyl transferase.

Events (n) Follow-up duration (person-years) Incidence rate (per 1,000 person-years) Model 1 Model 2 Model 3
Baseline GGT quartilesa
Q1 (n = 1,593,642) 3,254 10,166,664.8 0.32 1(Ref.) 1(Ref.) 1 (Ref.)
Q2 (n = 1,429,570) 2,726 9,141,060.0 0.30 0.95 (0.90–1.00) 0.86 (0.82–0.91) 1.06 (1.00–1.11)
Q3 (n = 1,519,057) 3,029 9,716,606.0 0.31 0.99 (0.94–1.04) 0.81 (0.77–0.85) 1.11 (1.06–1.17)
Q4 (n = 1,516,726) 3,048 9,638,948.5 0.32 1.08 (1.03–1.14) 0.76 (0.72–0.80) 1.15 (1.09–1.21)
P for trend  < 0.001  < 0.001  < 0.001
GGT ASV quartilesb
Q1 (n = 1,515,267) 2,405 9,645,912.3 0.25 1(Ref.) 1(Ref.) 1 (Ref.)
Q2 (n = 1,514,102) 2,649 9,732,995.2 0.27 1.08 (1.02–1.14) 1.03 (0.97–1.09) 1.01 (0.95–1.07)
Q3 (n = 1,514,878) 3,043 9,705,782.5 0.31 1.23 (1.17–1.30) 1.09 (1.04–1.15) 1.06 (1.01–1.12)
Q4 (n = 1,514,748) 3,960 9,578,589.3 0.41 1.59 (1.52–1.68) 1.27 (1.21–1.34) 1.12 (1.06–1.18)
P for trend  < 0.001  < 0.001  < 0.001

GGT, gamma-glutamyl transferase; ASV, average successive variability.

aQ1: 4–22 (men), 4–14 (women) U/L; Q2: 23–31(men), 15–18 (women) U/L; Q3: 32–50 (men), 19–25 (women) U/L; Q4: 51–1,000 (men), 26–1,000 (women) U/L.

bQ1: 1–1.16 (men), 1–1.15 (women) U/L; Q2: 1.16–1.27 (men), 1.15–1.26 (women) U/L; Q3: 1.27–1.45 (men), 1.26–1.45 (women) U/L; Q4: 1.45–79.47 (men), 1.45–76.59 (women) U/L. Model 1 is adjusted for age, sex, baseline estimated glomerular filtration rate and body mass index. Model 2 is the same as model 1 plus adjustments for moderate drinking, current smoking, regular exercise, and presence of diabetes, hypertension, and dyslipidemia. Model 3 is the same as model 2 plus adjustments for hemoglobin and an income in the lowest 20%. Additionally, baseline GGT was adjusted in the GGT ASV quartiles.